hCG — 10,000iu
279.99€
PT-141 — 10mg
The melanocortin peptide studied for central nervous system pathways of sexual function.
144.99€
Netto 144.99€
- In Stock
- Evidence tier: Established
- Format: Lyophilized
- Purity: 99.3%
- Vial size: 10mg
Wyłącznie do badań laboratoryjnych. Nie do stosowania u ludzi ani zwierząt.
O produkcie PT-141
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its effects on sexual function through central nervous system pathways rather than vascular mechanisms. Unlike PDE5 inhibitors that act peripherally, PT-141 works through melanocortin-4 receptors in the brain. It is one of the most studied peptides in sexual health research, with extensive published clinical data.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its effects on sexual function through central nervous system pathways rather than vascular mechanisms. Unlike PDE5 inhibitors that act peripherally, PT-141 works through melanocortin-4 receptors in the brain. It is one of the most studied peptides in sexual health research, with extensive published clinical data.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It activates MC3R and MC4R receptors in the hypothalamus, triggering downstream neural signaling cascades that modulate sexual arousal and desire through central nervous system pathways rather than peripheral vasodilation. The MC4R activation increases dopaminergic and oxytocinergic signaling in brain regions associated with sexual motivation. Notably, it works independently of nitric oxide/PDE5 pathways (unlike sildenafil/tadalafil).
Poznanie mechanizmu: Well-characterized
Tagi
Najważniejsze informacje
-
Ocena badań 9/10
186+ opublikowanych badań w zbiorze danych
-
Poziom dowodów: Established
Established — FDA-approved as Vyleesi for female HSDD. Multiple Phase 3 trials. Well-characterized mechanism. Clinical use in both genders supported by data.
-
Dane u ludzi
Multiple Phase III RCTs; FDA-approved as Vyleesi for HSDD in premenopausal women
Przechowywanie i obchodzenie się
Proszek liofilizowany: Room temperature or refrigerated
Po rekonstytucji: Refrigerate; use within 30 days
Bezpieczeństwo i ograniczenia
Badany w kontekście: Male erectile dysfunction, Female hypoactive sexual desire disorder, Libido enhancement, Sexual performance optimization
Zgłaszany początek działania: 45 minutes to 2 hours for onset; effects may last 6-12 hours
Zgłaszany czas trwania: As-needed basis — 0.5-2mg SC, 1-4 hours before activity. Max 8 doses/month (FDA labeling). NOT a daily cycle peptide.
Relacje społeczności: Users split: some report life-changing libido enhancement, others report severe nausea that outweighs benefits. Key tip: 'Start low (0.5mg) to assess nausea tolerance before going higher.' Men generally more positive. Brain-based mechanism is a major selling point for PDE5 inhibitor non-responders.
For research and educational use only. Source values are reproduced from the current PeptidesEuro content dataset and are not medical advice.
Jakość i specyfikacja
Product details
- Kod produktu
- L-PT141-10
- Dostępność
- In Stock
- Evidence tier
- Established
- Format
- Lyophilized
- Purity
- 99.3%
- Vial size
- 10mg
Dane do rekonstytucji
- Woda bakteriostatyczna
- 2 mL
- Stężenie
- 5mg/mL (5mcg per unit). Standard 1mg dose = 200 units (0.2mL). Starting dose 0.5mg = 100 units.
- Strzykawka
- 29-31G insulin
Parametry badawcze
- Ilość standardowa
- 1000 µg
- Ilość alternatywna
- 2000 µg
- Fiolka
- 10 mg
- Szacunek ze zbioru danych
- ~10 doses at 1mg each (1 vial of 10mg). As-needed use, not daily.
Raport laboratoryjny
- Laboratorium
- Janoshik Analytical
- Data badania
- 2026-03-01
- Dokument
- PDF nie jest dołączony
Zobacz badania
-
PMID 12851303
Czytaj badanie: PT-141: a melanocortin agonist for the treatment of sexual dysfunction (otwiera się w nowej karcie)
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Dose-dependent increase in erectile activity in healthy men and ED patients. Works through central melanocortin receptors, not peripheral vasodilation.
-
RECONNECT Phase 3 trials — Bremelanotide for HSDD in premenopausal women
Statistically significant improvement in sexual desire and reduction in distress scores in women with HSDD. Basis for FDA approval of Vyleesi in 2019.
-
PT-141 in male erectile dysfunction: efficacy in PDE5 inhibitor non-responders
Effective in men who had failed PDE5 inhibitors (Viagra/Cialis). Works through entirely different CNS pathway — melanocortin vs nitric oxide/PDE5.
Badania podano w celach informacyjnych. Większość przeprowadzono na modelach zwierzęcych lub komórkowych; ich wyniki nie dowodzą bezpieczeństwa ani działania u ludzi.
Dalsza lektura
Community evidence
- Source window English Reddit Updated 13 Aug 2026 · 10-year window
- Coverage confidence Low Confidence in the available community sample
- Distribution Pending Not enough data for a distribution.
Selected reports
-
5 years agor/SEXONDRUGS · Post
I really don't like being punctured, so I'll go ahead and say that injecting it is the biggest downside. … At first I felt sick and weak, I was gonna go for a run but instead I laid down for 30 minutes.
Based on 1 qualifying reports from 1 threads. 26 candidates excluded as duplicates, promotion, deleted content, or lacking concrete personal experience. Reddit self-reports are not medical evidence or proof of causation.
Pytania o PT-141
Pytania i odpowiedzi zapisane dla tego produktu.
PT-141 works through the central nervous system (melanocortin receptors in the brain) to increase sexual desire and arousal. Viagra and Cialis work peripherally by increasing blood flow through PDE5 inhibition. PT-141 affects desire, not just mechanics — which is why it works in some people who don't respond to PDE5 inhibitors. It's also one of the few compounds studied for female sexual dysfunction.
PT-141 is used as-needed, not on a daily cycle like most peptides. FDA labeling for Vyleesi recommends no more than 1 dose per 24 hours and no more than 8 doses per month. Most research protocols use 0.5-2mg SC administered 1-4 hours before anticipated activity. Start at the low end (0.5mg) to assess nausea tolerance before increasing.
Nausea is the most commonly reported side effect — approximately 40% of women in clinical trials experienced it. In men, rates are lower but still notable. The nausea is typically transient (30-60 minutes) and dose-dependent. Community tip: start at 0.5mg and increase gradually. Taking it on an empty stomach and staying hydrated may help.
Opinie
Ten produkt nie ma jeszcze opinii.
Powiązane produkty
Jak działa zamawianie
Dane produktu, źródła i zamówienie pozostają ze sobą powiązane.
-
Wybierz związek
Wybierz związek i rozmiar fiolki w katalogu.
-
Sprawdź informacje o produkcie
Otwórz szczegóły produktu i powiązane badania.
-
Zachowaj źródła
Zapisz źródła do swojej dokumentacji.
Dlaczego zamawiać w PeptidesEuro
Profile związków
Struktura, dostępne rozmiary i uwagi dotyczące obchodzenia się w jednym miejscu.
Źródła badań
Strony produktów prowadzą do badań dotyczących każdego związku.
Jedna historia zamówień
Zamówienia i ich szczegóły pozostają na Twoim koncie.
Przejrzyste dane produktu
Cena, dostępność i podatek przy każdym produkcie.
PeptidesEuro is a research materials supplier operated by Pepticore LLC. We provide high-purity peptides and research compounds for in-vitro laboratory and scientific research purposes. All products are sold strictly for research use only and are not intended for human or animal consumption.
No. All products sold through meimx.com are intended strictly for in-vitro laboratory and scientific research purposes only. They are not intended for human or animal consumption, injection, ingestion, inhalation, or any form of administration to living organisms. By purchasing from PeptidesEuro, you acknowledge and agree to these terms as outlined in our Terms of Service.
No. Our products have not been evaluated, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. They are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. PeptidesEuro is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
No. PeptidesEuro does not provide medical advice, treatment recommendations, or dosing instructions. Any information on our website, including product descriptions and referenced research, is provided for educational and informational purposes only. If you have medical questions, please consult a licensed healthcare provider.
Research Use Only means that our products are sold exclusively as reference standards and research materials for use in laboratory and scientific research settings. Purchasers agree to use all products solely for legitimate research purposes in compliance with all applicable laws and regulations.
Gotowy, by zamówić PT-141?
Przeglądaj katalog albo odpowiedz na jedno pytanie w wyszukiwarce produktów.